Organization (Other)
National Cancer Center, Japan
ClinicalTrials.gov lists National Cancer Center, Japan as lead sponsor of 17 trials. It has 40 active development programs and 13 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs. 2 trials are registered to start in 2027 or later.
This page covers National Cancer Center, Japan: 17 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (34)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Head and Neck Neoplasms | 4 |
| Breast Neoplasms | 3 |
| Carcinoma, Squamous Cell | 2 |
| Esophageal Neoplasms | 2 |
| Esophageal Squamous Cell Carcinoma | 2 |
Showing 5 of 34 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 2 |
| 2024 | 1 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 5 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 1 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (40)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Chemoradiotherapy | Head and Neck Neoplasms | Phase 3 | 1 |
| Chemoradiotherapy | Esophageal Neoplasms | Phase 3 | 1 |
| Chemoradiotherapy | Carcinoma, Squamous Cell | Phase 3 | 1 |
| Chemoradiotherapy | Esophageal Squamous Cell Carcinoma | Phase 3 | 1 |
| Tamoxifen | Breast Neoplasms | Phase 3 | 1 |
Showing 5 of 40 active programs.
Approved assets (13)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Palbociclib | 1 |
| Tamoxifen | 1 |
| Cefmetazole (drug) | 1 |
| Goserelin | 1 |
| CARBOPLATIN | 1 |
Showing 5 of 13 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 2 of 2 hit target (n=2) | 1 of 2 on time (n=2) |
Journals published in (27)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 8 |
| Annals of oncology : official journal of the European Society for Medical Oncology | 2 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 2 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2 |
| Lung cancer (Amsterdam, Netherlands) | 2 |
Showing 5 of 27 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 5 | 5 | 2023-04-25 |
Organization relationships (6)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Regina Elena Cancer Institute | Co sponsors trial with | 1 |
| Fiverings Co., Ltd. | Co sponsors trial with | 1 |
| Princess Margaret Hospital, Canada | Co sponsors trial with | 1 |
| Medical Center Haaglanden | Co sponsors trial with | 1 |
| Universitäts-Frauenklinik Graz | Co sponsors trial with | 1 |
Showing 5 of 6 relationships.
Latest dated events (29)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 29 events.
Biomarker capability evidence (141)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 141 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.